HEPA Archives - BioTuesdays

Executive Moves

Hepion adds accomplished biopharmaceutical executives Anand Reddi and Dr. Kaouthar Lbiati to board

Anand Reddi, M.S. Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its board of directors, effective immediately. “Mr. Reddi and Dr. Lbiati have a remarkable wealth...

June 28, 2022

Developments

Hepion receives FDA orphan drug designation for rencofilstat in HCC

The FDA granted orphan drug designation to Hepion Pharmaceuticals’ (NASDAQ:HEPA) drug candidate, rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibitor, for the treatment of hepatocellular...

June 20, 2022

Executive Moves

Hepion names accomplished life sciences veteran Launa Aspeslet as COO

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Launa Aspeslet, Ph.D., RAC, as chief operating officer to support the company’s rencofilstat clinical program. A versatile C-level executive with more than 25 years of...

June 14, 2022

Developments

Hepion highlights upcoming Phase 2 rencofilstat trials at NASH Congress

Todd Hobbs, M.D. and CMO of Hepion Pharmaceuticals (NASDAQ:HEPA), gave a clinical presentation entitled, “Rencofilstat (CRV431): A liver-targeting drug candidate for NASH and HCC” at the Global NASH Congress...

May 27, 2022

Developments

Hepion Pharma, HepQuant in clinical collaboration for Phase 2b NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) entered into a clinical collaboration with HepQuant, a closely-held Denver company with novel, proprietary investigational technology for evaluating liver function and health in...

May 3, 2022

Markets

Cantor starts Hepion Pharma at OW; PT $3.50

Cantor Fitzgerald launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with an “overweight” rating and $3.50 price target. The stock closed at $1.03 on Feb. 25. Hepion’s lead asset, Rencofilstat (CRV431)...

February 28, 2022

Executive Moves

Hepion names world-renowned hepatologist, Dr. Eddie Cheung, to lead strategic medical affairs in Asia

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Eddie Cheung, M.D., FACG, to lead the company’s strategic medical affairs in Asia, a newly-created position. Dr. Cheung will explore and identify possible...

February 15, 2022

Developments

Hepion’s rencofilstat combined with an immune checkpoint inhibitor demonstrates synergistic anti-tumor activity in a non-clinical liver cancer study

Results of a non-clinical research study demonstrated that Hepion Pharmaceuticals’ (NASDAQ:HEPA) clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse...

January 26, 2022

Developments

Rencofilstat adopted as non-proprietary name for Hepion’s CRV431

Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases, CRV431, has been renamed, rencofilstat. The non-proprietary name change was...

January 7, 2022

Developments

Hepion Pharmaceuticals to present clinical data at NASH-TAG conference

Dr. Todd Hobbs, CMO of Hepion Pharmaceuticals (NASDAQ:HEPA), will present data from the company’s Phase 2 AMBITION study with drug candidate, CRV431, at the NASH-TAG 2022 conference at Park City, Utah on Jan. 8...

January 5, 2022

Tag - HEPA

Hepion adds accomplished biopharmaceutical executives Anand Reddi and Dr. Kaouthar Lbiati to board

Hepion receives FDA orphan drug designation for rencofilstat in HCC

Hepion names accomplished life sciences veteran Launa Aspeslet as COO

Hepion highlights upcoming Phase 2 rencofilstat trials at NASH Congress

Hepion Pharma, HepQuant in clinical collaboration for Phase 2b NASH trial

Cantor starts Hepion Pharma at OW; PT $3.50

Hepion names world-renowned hepatologist, Dr. Eddie Cheung, to lead strategic medical affairs in Asia

Hepion’s rencofilstat combined with an immune checkpoint inhibitor demonstrates synergistic anti-tumor activity in a non-clinical liver cancer study

Rencofilstat adopted as non-proprietary name for Hepion’s CRV431

Hepion Pharmaceuticals to present clinical data at NASH-TAG conference

General

More